靶向治疗的潜在风险。 - Suppr

Suppr

超能文献

The possible perils of targeted therapy.

作者信息

Duffner U, Abdel-Mageed A, Younge J, Tornga C, Scott K, Staddon J, Elliott K, Stumph J, Kidd P

机构信息

Division of Pediatric Blood & Bone marrow Transplantation at Helen DeVos Children's Hospital, Grand Rapids, MI, USA.

Spectrum Health and Michigan State University, Department of Pediatrics & Human Development, Grand Rapids, MI, USA.

出版信息

Leukemia. 2016 Jul;30(7):1619-21. doi: 10.1038/leu.2016.18. Epub 2016 Feb 9.

DOI:10.1038/leu.2016.18

PMID:26859079

Abstract

摘要

相似文献

The possible perils of targeted therapy.

Leukemia. 2016 Jul;30(7):1619-21. doi: 10.1038/leu.2016.18. Epub 2016 Feb 9.

Blinatumomab significantly improves overall survival.

Lancet Oncol. 2017 Apr;18(4):e203. doi: 10.1016/S1470-2045(17)30183-3. Epub 2017 Mar 10.

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in -rearranged infant ALL.

Blood Adv. 2018 Jun 26;2(12):1382-1385. doi: 10.1182/bloodadvances.2018018093.

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Blood Cancer J. 2018 Aug 22;8(9):80. doi: 10.1038/s41408-018-0117-0.

Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.

Pediatr Blood Cancer. 2024 Jun;71(6):e30964. doi: 10.1002/pbc.30964. Epub 2024 Mar 21.

Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.

Ann Hematol. 2017 Sep;96(9):1579-1581. doi: 10.1007/s00277-017-3050-6. Epub 2017 Jun 20.

Phase 1/2 study of blinatumomab in relapsed paediatric ALL.

Lancet Oncol. 2016 Dec;17(12):e525. doi: 10.1016/S1470-2045(16)30580-0. Epub 2016 Nov 11.

Blinatumomab for paediatric mixed phenotype acute leukaemia.

Br J Haematol. 2021 Oct;195(2):289-292. doi: 10.1111/bjh.17707. Epub 2021 Jul 12.

Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.

J Pediatr Hematol Oncol. 2020 May;42(4):e258-e261. doi: 10.1097/MPH.0000000000001572.

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26594. Epub 2017 Apr 28.

引用本文的文献

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Blood. 2025 Jul 24;146(4):437-455. doi: 10.1182/blood.2024026655.

Evolutionary genomic analysis for ALL.

Nat Cancer. 2023 Aug;4(8):1058-1059. doi: 10.1038/s43018-023-00605-z.

Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.

Sci Rep. 2021 Oct 5;11(1):19794. doi: 10.1038/s41598-021-99347-0.

Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation.

Am J Cancer Res. 2021 Jun 15;11(6):3111-3122. eCollection 2021.

[CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].

Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):282-286. doi: 10.3760/cma.j.issn.0253-2727.2020.04.004.

Immunotherapy- (Blinatumomab-) Related Lineage Switch of Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.

Case Rep Hematol. 2019 Dec 7;2019:7394619. doi: 10.1155/2019/7394619. eCollection 2019.

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.

Blood Cancer J. 2017 Sep 15;7(9):e607. doi: 10.1038/bcj.2017.89.

Antigen Loss Variants: Catching Hold of Escaping Foes.

Front Immunol. 2017 Feb 24;8:175. doi: 10.3389/fimmu.2017.00175. eCollection 2017.

本文引用的文献

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.

Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13.

MLL leukemia and future treatment strategies.

Arch Pharm (Weinheim). 2015 Apr;348(4):221-8. doi: 10.1002/ardp.201400449. Epub 2015 Mar 4.

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10.

CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Leukemia. 2014 Mar;28(3):609-20. doi: 10.1038/leu.2013.354. Epub 2013 Nov 25.

Lineage switch in childhood acute leukemia: an unusual event with poor outcome.

Am J Hematol. 2012 Sep;87(9):890-7. doi: 10.1002/ajh.23266. Epub 2012 Jun 8.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

Acute monocytic leukaemia originating from MLL-MLLT3-positive pre-B cells.

Br J Haematol. 2010 Sep;150(5):621-3. doi: 10.1111/j.1365-2141.2010.08239.x. Epub 2010 May 20.

Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1(Suppl 1):11842-9. doi: 10.1073/pnas.2034201100. Epub 2003 Sep 22.

Bipotential B-macrophage progenitors are present in adult bone marrow.

Nat Immunol. 2001 Jan;2(1):83-8. doi: 10.1038/83210.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验